Form 3 Biohaven Pharmaceutical For: Jun 15 Filed by: Mehta Kishan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
June 17, 2021 9:51 PM EDT
| FORM
3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act
of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Expires: |
December 31, 2014 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person
*
| C/O BIOHAVEN PHARMACEUTICALS, INC. |
| 215 CHURCH STREET |
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
06/15/2021
|
3. Issuer Name
and
Ticker or Trading Symbol
Biohaven Pharmaceutical Holding Co Ltd.
[
BHVN
]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check
Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting
Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
|
Common Shares
|
8,765
|
D
|
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
|
Stock Options (Right to buy)
|
|
12/18/2029 |
Common Shares
|
15,000
|
52.13
|
D
|
|
|
Stock Options (Right to buy)
|
|
01/17/2029 |
Common Shares
|
20,000
|
37.56
|
D
|
|
|
Restricted Share Unit Award
(3)
|
|
|
Common Shares
|
3,750
|
(3)
|
D
|
|
| Explanation of Responses: |
|
|
|
|
|
| Remarks: |
| Exhibit 24.1 - Power of Attorney |
|
/s/ Jim Engelhart, Attorney-in-Fact |
06/17/2021 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Exhibit 24.1
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby
constitutes and appoints each of Vlad
Coric, James Engelhart and Douglas Gray, or either of them signing
singly, and with full power of
substitution, the undersigned's true and lawful attorney-in-fact to:
(1) prepare, execute in the undersigned's name and on the
undersigned's behalf, and submit to
the U.S. Securities and Exchange Commission (the "SEC") any documents
necessary or
appropriate to obtain codes and passwords enabling the undersigned to
make electronic
filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of
1934 or any rule or regulation of the SEC;
(2) execute for and on behalf of the undersigned Forms 3, 4, and 5
in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and the rules
thereunder;
(3) do and perform any and all acts for and on behalf of the
undersigned which may be
necessary or desirable to complete and execute any such Form 3, 4, or
5, complete and
execute any amendment or amendments thereto, and timely file such
form with the SEC
and any stock exchange or similar authority; and
(4) take any other action of any type whatsoever in connection with
the foregoing which, in the
opinion of such attorney-in-fact, may be of benefit to, in the best
interest of, or legally
required by, the undersigned, it being understood that the documents
executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power
of Attorney shall be in
such form and shall contain such terms and conditions as such
attorney-in-fact may
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and
perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might
or could do if personally present, with full power of substitution or
revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully
do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of
the undersigned, are not assuming, any of the undersigned's
responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and
effect until the undersigned is no longer
required to file Forms 3, 4, and 5 with respect to the undersigned's
holdings of and transactions in
securities issued by Biohaven Pharmaceutical Holding Company Ltd.,
unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of
this 17th day of June, 2021.
/s/Kishan Mehta
Signature
Kishan Mehta
Print Name
Tweet
Share
E-mail
